OverviewSuggest Edit

Aytu BioScience is a specialty pharmaceutical company focused on developing and commercializing novel products in the field of urology. Aytu is initially concentrating on hypogonadism, prostate cancer, male infertility, and plans to expand into other urological indications for which there are significant medical needs.
The Company currently markets Natesto (testosterone) nasal gel, the only FDA-approved nasally administered testosterone. Natesto is an androgen indicated for replacement therapy in adult males with a deficiency or absence of endogenous testosterone due to primary hypogonadism (congenital or acquired) or hypogonadotropic hypogonadism.

TypePublic
HQEnglewood, US
Websiteaytubio.com
Employee Ratings2.1

Latest Updates

Employees (est.) (Dec 2017)1
Revenue (FY, 2017)$3.2 M(+26%)
Share Price (May 2019)$1.9 (+7%)

Key People/Management at Aytu BioScience

Josh Disbrow

Josh Disbrow

Chairman & Chief Executive Officer
Jarrett Disbrow

Jarrett Disbrow

COO
David Green

David Green

CFO
Show more

Aytu BioScience Office Locations

Aytu BioScience has an office in Englewood
Englewood, US (HQ)
373 Inverness Pkwy #206
Show all (1)

Aytu BioScience Financials and Metrics

Aytu BioScience Revenue

Aytu BioScience's revenue was reported to be $3.22 m in FY, 2017
USD

Revenue (Q3, 2019)

2.4m

Gross profit (Q3, 2019)

1.8m

Gross profit margin (Q3, 2019), %

74.1%

Net income (Q3, 2019)

(4.5m)

EBIT (Q3, 2019)

(4.3m)

Market capitalization (21-May-2019)

31.8m

Closing stock price (21-May-2019)

1.9

Cash (31-Mar-2019)

14.6m
Aytu BioScience's current market capitalization is $31.8 m.
Annual
USDFY, 2013FY, 2015FY, 2016FY, 2017FY, 2018

Revenue

1.8k261.8k2.6m3.2m

Revenue growth, %

879%

Cost of goods sold

88.1k957.1k1.4m2.1m

Gross profit

173.7k1.6m1.8m
Quarterly
USDQ1, 2014Q2, 2014Q3, 2014Q2, 2016Q3, 2016Q1, 2017Q2, 2017Q3, 2017Q1, 2018Q2, 2018Q3, 2018Q1, 2019Q2, 2019Q3, 2019

Revenue

1.0k469.2k668.5k698.0k794.2k893.5k1.1m1.1m607.5k1.4m1.8m2.4m

Cost of goods sold

244.1k340.8k191.9k551.3k324.4k287.2k385.4k1.1m411.0k525.1k616.9k

Gross profit

225.1k327.7k506.1k242.9k569.1k789.2k665.7k(529.4k)1.0m1.3m1.8m

Gross profit Margin, %

48%49%73%31%64%73%63%(87%)71%71%74%
Annual
USDFY, 2013FY, 2015FY, 2016FY, 2017FY, 2018

Cash

1.9k7.4m8.1m802.3k7.0m

Accounts Receivable

157.1k162.4k528.0k578.8k

Inventories

39.4k524.7k1.3m1.3m

Current Assets

1.9k8.1m10.1m3.0m9.5m
Quarterly
USDQ4, 2013Q1, 2014Q2, 2014Q3, 2014Q2, 2016Q3, 2016Q1, 2017Q2, 2017Q3, 2017Q1, 2018Q2, 2018Q3, 2018Q1, 2019Q2, 2019Q3, 2019

Cash

1.9k445.0184.09.0k11.0m8.7m2.7m5.2m3.5m7.0m3.9m12.0m4.0m17.8m14.6m

Accounts Receivable

288.5k84.3k509.4k582.4k342.5k1.2m1.4m732.5k760.1k1.5m1.4m

Inventories

653.1k621.4k585.4k439.0k208.2k1.2m1.4m883.8k1.3m1.6m1.5m

Current Assets

1.9k552.0213.09.3k12.8m10.4m6.4m8.2m4.4m9.7m7.7m14.6m6.9m22.0m18.5m
Annual
USDFY, 2013FY, 2015FY, 2016FY, 2017FY, 2018

Net Income

(57.3k)(7.7m)(28.2m)(22.5m)(10.2m)

Depreciation and Amortization

4.9k118.2k874.8k4.4m2.6m

Inventories

195.4k(26.8k)

Accounts Payable

6.7k547.3k1.6m
Quarterly
USDQ1, 2014Q2, 2014Q3, 2014Q2, 2016Q3, 2016Q1, 2017Q2, 2017Q3, 2017Q1, 2018Q2, 2018Q3, 2018Q1, 2019Q2, 2019Q3, 2019

Net Income

(16.5k)(38.7k)(50.5k)(5.6m)(12.9m)(5.7m)(10.5m)(15.8m)(4.2m)(7.9m)(10.7m)(3.4m)(8.1m)(12.6m)

Depreciation and Amortization

1.2k2.4k3.6k242.4k433.5k822.2k1.7m2.3m653.3k1.3m2.0m556.8k1.2m2.0m

Inventories

85.7k291.0k141.0k(67.6k)428.4k28.9k(191.1k)

Accounts Payable

7.4k19.4k(2.0)
USDY, 2019

Financial Leverage

2.4 x
Show all financial metrics

Aytu BioScience Blogs

Aytu BioScience Announces Natesto(R) Presentations at Two Upcoming Scientific Conferences

Aytu BioScience Announces Natesto(R) Presentations at Two Upcoming Scientific Conferences

Aytu BioScience Announces ZolpiMist(TM) Global Distribution Agreement with SUDA Pharmaceuticals

Aytu BioScience Announces ZolpiMist(TM) Global Distribution Agreement with SUDA Pharmaceuticals

Aytu BioScience Reports 71% Revenue Growth in Q2 FY19

Aytu BioScience Reports 71% Revenue Growth in Q2 FY19

Aytu BioScience to Report Fiscal Second Quarter 2019 Results and Business Update

Aytu BioScience to Report Fiscal Second Quarter 2019 Results and Business Update

Aytu BioScience Announces U.S. Field Sales Launch of Tuzistra(R) XR

Aytu BioScience Announces U.S. Field Sales Launch of Tuzistra(R) XR

Aytu BioScience Provides Natesto(R) Commercial Update for the Quarter Ending December 31, 2018, Reports 27% Prescription Growth and Expansion of Natesto(R) Direct Program

Aytu BioScience Provides Natesto(R) Commercial Update for the Quarter Ending December 31, 2018, Reports 27% Prescription Growth and Expansion of Natesto(R) Direct Program
Show more

Aytu BioScience Frequently Asked Questions

  • Who are Aytu BioScience key executives?

    Aytu BioScience's key executives are Josh Disbrow, Jarrett Disbrow and David Green.

  • How many employees does Aytu BioScience have?

    Aytu BioScience has 1 employees.

  • Who are Aytu BioScience competitors?

    Competitors of Aytu BioScience include Obsidian Therapeutics, Mymetics and Elite Pharmaceuticals.

  • Where is Aytu BioScience headquarters?

    Aytu BioScience headquarters is located at 373 Inverness Pkwy #206, Englewood.

  • Where are Aytu BioScience offices?

    Aytu BioScience has an office in Englewood.

  • How many offices does Aytu BioScience have?

    Aytu BioScience has 1 office.